Reference Lists for ASTROnews Winter 2022 Issue

Page 2: Editor’s Notes – Time for a Reset

1. Kratzer TB, Siegel RL, Miller KD, et al. Progress Against Cancer Mortality 50 Years After Passage of the National Cancer Act. JAMA Oncol. Published online November 11, 2021. doi:10.1001/jamaoncol.2021.5668
2. Keating NL, Jhatakia S, Brooks GA, et al: Association of Participation in the Oncology Care Model With Medicare Payments, Utilization, Care Delivery, and Quality Outcomes. JAMA. 2021;326(18):1829-1839. doi:10.1001/jama.2021.17642
3. Centers for Medicare and Medicaid Services. Medicare Part B Drug Spending Dashboard. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Information-on-Prescription-Drugs/MedicarePartB. Accessed December 24, 2021
4. Ziakas PD, Mylonakis E. Medicare Part D Spending on Drugs Prescribed by Oncologists: Temporal Trends and Regional Variation. JCO Oncol Pract. 2021 Mar;17(3):e433-e439. doi:10.1200/OP.20.00165
5. Beaver, JA, Pazdur R. “Dangling” Accelerated Approvals in Oncology. N Engl J Med. 2021; 384:e68. doi: 10.1056/NEJMp2104846

Page 13: Science Highlights - Gastrointestinal

1. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002 Mar 1;20(5):1167-74. doi:10.1200/JCO.2002.20.5.1167
2. Hulshof MCCM, Geijsen ED, Rozema T, et al. Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study). J Clin Oncol. 2021 Sep 1;39(25):2816-2824. doi:10.1200/JCO.20.03697
3. Lin SH, Hobbs BP, Verma V, et al. Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. J Clin Oncol. 2020 May 10;38(14):1569-1579. doi:10.1200/JCO.19.02503
4. Goodman KA, Ou FS, Hall NC, et al. Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial. J Clin Oncol. 2021 Sep 1;39(25):2803-2815. doi:10.1200/JCO.20.03611
5. Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009 Apr 10;27(11):1806-13. doi:10.1200/JCO.2008.17.7188
6. AlMasri SS, Zenati M, Hammad A, et al. Implications of SMAD4 Status in Pancreatic Carcinoma Treated With Radiation Therapy: A Multi-Institutional Analysis. Int J Radiat Biol Phys. 2021 Nov 1;111(3):S145. doi:10.1016/j.ijrobp.2021.07.326
7. Ben-Josef E, Winter K, William TM, et al. β-Catenin is Independently Associated With Outcome in Pancreatic Cancer: An Analysis of NRG Oncology/RTOG 9704. Int J Radiat Biol Phys. 2021 Nov 1;111(3):S146-S147. doi:10.1016/j.ijrobp.2021.07.328

Page 17: Science Highlights - Head and Neck

1. Wu J, Xiao F, Zheng Y, Lin Y, Hong-Liang W. Worldwide trend in human papillomavirus-attributed cancer incidence rates between 1990 and 2021 and Bayesian projection to 2030. Cancer. 127(17); Sep 2021, 3172-3182. doi:10.1002/cncr.33628
2. Barsoum IB, Smallwood CA, Siemens DR, Graham CH. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res. 2014 Feb 1;74(3):665-74. doi:10.1158/0008-5472
3. Overgaard J. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck--a systematic review and meta-analysis. Radiother Oncol. 2011 Jul;100(1):22-32. doi:10.1016/j.radonc.2011.03.004
4. Overgaard J, Hansen HS, Overgaard M, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol. 1998 Feb;46(2):135-46. doi:10.1016/s0167-8140(97)00220-x
5. Brooks JM, Menezes AN, Ibrahim M, et al. Development and Validation of a Combined Hypoxia and Immune Prognostic Classifier for Head and Neck Cancer. Clin Cancer Res. 2019; 25:5315-28. doi:10.1158/1078-0432.CCR-18-3314

Page 24: Edu 18 - Priming the Immune System Prior to CAR T Cell Therapy: An Emerging Role of Radiation

1. McBride WH, Chiang CS, Olson JL, et al. A sense of danger from radiation. Radiat Res. 2004;162(1):1-19. doi:10.1667/rr3196
2. Zhang B, Bowerman NA, Salama JK, et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med. 2007;204(1):49-55. doi:10.1084/jem.20062056
3. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377(26):2531-2544. doi:10.1056/NEJMoa1707447
4. Schuster SJ, Svoboda J, Chong EA, et al. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. N Engl J Med. 2017;377(26):2545-2554. doi:10.1056/NEJMoa1708566
5. Pinnix CC, Gunther JR, Dabaja BS, et al. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Adv. 2020 Jul 14;4(13): 2871-2883. doi: 10.1182/bloodadvances.2020001837
6. Imber BS, Sadelain M, DeSelm C, et al. Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy. Br J Haematol. 2020 Jul;190(1):45-51. doi:10.1111/bjh.16541